journal article·2018-11-21

Cancer Theranostic Applications of Albumin-Coated Tobacco Mosaic Virus Nanoparticles

A. S. Pitek, H. Hu, S. Shukla, N. F. Steinmetz

ACS Applied Materials & Interfaces· Volume 10· Issue 46
Publisher page

Abstract

Nanotechnology holds great promise in cancer drug delivery, and of particular interest are theranostic approaches in which drug delivery and imaging are integrated. In this work, we studied and developed the plant virus tobacco mosaic virus (TMV) as a platform nanotechnology for drug delivery and imaging. Specifically, a serum albumin (SA)-coated TMV formulation was produced. The SA coating fulfils two functions: SA provides a stealth coating for enhanced biocompatibility; it also acts as a targeting ligand enabling efficient tumor accumulation of SA-TMV versus TMV in mouse models of breast and prostate cancer. We demonstrate drug delivery of the chemotherapy doxorubicin (DOX); TMV-delivered DOX outperformed free DOX, resulting in significant delayed tumor growth and increased survival. Furthermore, we demonstrated the ability of SA-coated TMV loaded with chelated Gd(DOTA) for magnetic resonance imaging detection of tumors. In the future, we envision the application of such probes as theranostic, where first imaging is performed to assess whether the nanoparticles are effective at targeting a particular patient tumor. If targeting is confirmed, the therapeutic would be added and treatment can begin. The combination of imaging and therapy would allow to monitor disease progression and therefore inform about the effectiveness of the drug delivery approach.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bacteriophages and microbial interactions · Virus-based gene therapy research · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States

Department of NanoEngineering, Moores Cancer Center, University of California—San Diego, La Jolla, California 92093, United States

Funding

National Cancer Institute

References (33)

Show source-provided references
1. 10.1016/j.jconrel.2011.09.06310.1016/j.jconrel.2011.09.063 ↗
2. 10.1517/1742524090357997110.1517/17425240903579971 ↗
3. Vannucci L. · New Microbiol. · 2013 · 36 · 1
4. 10.3390/biomedicines503004410.3390/biomedicines5030044 ↗
5. 10.1007/978-94-007-6552-8_2210.1007/978-94-007-6552-8_22 ↗
6. 10.1002/adhm.20140064110.1002/adhm.201400641 ↗
7. 10.1073/pnas.060099710310.1073/pnas.0600997103 ↗
8. 10.1126/science.395249010.1126/science.3952490 ↗
9. 10.1021/ja046239n10.1021/ja046239n ↗
10. 10.1039/C7TB03106H10.1039/C7TB03106H ↗
11. 10.1016/j.biomaterials.2016.02.03210.1016/j.biomaterials.2016.02.032 ↗
12. 10.1002/cbic.20070055910.1002/cbic.200700559 ↗
13. 10.1021/acsami.6b0280110.1021/acsami.6b02801 ↗
14. 10.1016/j.jconrel.2016.02.04510.1016/j.jconrel.2016.02.045 ↗
15. 10.1039/c6nr09099k10.1039/c6nr09099k ↗
16. 10.1021/mp300205710.1021/mp3002057 ↗
17. 10.2217/nnm-2016-042110.2217/nnm-2016-0421 ↗
18. 10.1021/acsnano.5b0736010.1021/acsnano.5b07360 ↗
19. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
20. 10.1002/smll.20150245810.1002/smll.201502458 ↗
21. 10.1152/ajpheart.1992.262.1.h24610.1152/ajpheart.1992.262.1.h246 ↗
22. 10.3390/ijms1807155610.3390/ijms18071556 ↗
23. 10.3892/or.15.5.139710.3892/or.15.5.1397 ↗
24. 10.3892/ol.2016.439910.3892/ol.2016.4399 ↗
25. 10.1593/tlo.0910910.1593/tlo.09109 ↗
26. 10.7150/thno.1668410.7150/thno.16684 ↗
27. 10.1021/acs.molpharmaceut.8b0012610.1021/acs.molpharmaceut.8b00126 ↗
28. 10.1021/nl404816m10.1021/nl404816m ↗
29. 10.1021/nl060378g10.1021/nl060378g ↗
30. 10.1002/mrm.2061410.1002/mrm.20614 ↗
31. 10.1021/acsnano.7b0447210.1021/acsnano.7b04472 ↗
32. 10.1039/c3nr33724c10.1039/c3nr33724c ↗
33. 10.1002/mrm.2254410.1002/mrm.22544 ↗